Anbio Biotechnology Class A Ordinary Shares (NASDAQ:NNNN) — Stock Price
Anbio Biotechnology Class A Ordinary Shares (NASDAQ:NNNN) is currently trading at $10.19 USD, down 3.96% today. Over the past 52 weeks, shares have ranged between $9.12 and $52.10. This page tracks Anbio Biotechnology Class A Ordinary Shares's live share price on the NASDAQ exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Anbio Biotechnology Class A Ordinary Sha market capitalisation.
Anbio Biotechnology Class A Ordinary Shares (NNNN) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Anbio Biotechnology Class A Ordinary Shares's daily closing share price and trading volume on the NASDAQ exchange over the past year, giving a clear view of recent price momentum and liquidity.
Anbio Biotechnology Class A Ordinary Shares Income Statement — Revenue, Profit & Earnings by Year
Anbio Biotechnology Class A Ordinary Shares's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Revenue | $9.76 Million | $8.19 Million | $6.71 Million | $23.54 Million | $4.43 Million |
| Cost of Revenue | $1.25 Million | $2.30 Million | $3.35 Million | $10.98 Million | $1.89 Million |
| Gross Profit | $8.51 Million | $5.89 Million | $3.36 Million | $12.56 Million | $2.54 Million |
| Research & Development | $227.19K | $454.23K | $134.70K | $200.00K | $0.00 |
| SG&A | $1.57 Million | $3.44 Million | $1.27 Million | $2.17 Million | $86.09K |
| Total Operating Expenses | $2.00 Million | $3.89 Million | $1.40 Million | $2.37 Million | $86.09K |
| Operating Income | $6.51 Million | $2.00 Million | $1.96 Million | $10.20 Million | $2.46 Million |
| EBITDA | $6.51 Million | $2.57 Million | $2.27 Million | $10.03 Million | $2.54 Million |
| EBIT | — | $2.00 Million | $2.25 Million | $10.02 Million | $2.46 Million |
| Interest Expense | — | $0.00 | $0.00 | $8.00K | $0.00 |
| Income Before Tax | $7.23 Million | $2.37 Million | $2.25 Million | $10.01 Million | $2.54 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | $7.23 Million | $2.37 Million | $2.25 Million | $10.01 Million | $2.54 Million |
Anbio Biotechnology Class A Ordinary Shares Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Anbio Biotechnology Class A Ordinary Shares's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total Assets | $30.24 Million | $18.92 Million | $15.81 Million | $13.96 Million | $4.92 Million |
| Total Current Assets | $30.24 Million | $18.53 Million | $15.75 Million | $13.94 Million | $4.92 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | $4.13 Million | $0.00 | $0.00 | $1.57 Million | $0.00 |
| Net Receivables | $3.66 Million | $1.06 Million | $1.88 Million | $3.58K | $717.50K |
| Inventory | — | — | $0.00 | $353.87K | $0.00 |
| Property, Plant & Equipment | — | — | — | — | — |
| Goodwill | — | — | — | — | — |
| Total Liabilities | $87.84K | $1.73 Million | $993.06K | $1.41 Million | $2.38 Million |
| Total Current Liabilities | $87.84K | $1.73 Million | $993.06K | $1.41 Million | $2.38 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | $-7.77 Million | $-11.76 Million | $-9.69 Million | $-7.10 Million | $-4.18 Million |
| Total Stockholder Equity | $30.16 Million | $17.19 Million | $14.82 Million | $12.55 Million | $2.54 Million |
| Retained Earnings | $23.58 Million | $17.17 Million | $14.80 Million | $12.55 Million | $2.54 Million |
Anbio Biotechnology Class A Ordinary Shares Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Anbio Biotechnology Class A Ordinary Shares generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Cash Flow | $-6.74 Million | $2.08 Million | $898.37K | $4.45 Million | $4.18 Million |
| Capital Expenditures | $0.00 | $0.00 | $0.00 | $2.88 | $0.00 |
| Free Cash Flow | $-6.74 Million | $2.08 Million | $898.37K | $4.45 Million | $4.18 Million |
| Investing Cash Flow | $-4.20 Million | $337.10K | $1.73 Million | $-1.53 Million | — |
| Financing Cash Flow | $6.95 Million | $-344.61K | $-42.84K | $0.00 | — |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | — | $0.00 | $12.06K | $6.25K | $0.00 |
| Change in Cash | $-3.99 Million | $2.07 Million | $2.59 Million | $2.92 Million | $4.18 Million |
Anbio Biotechnology Class A Ordinary Shares Earnings History — EPS Actual vs. Analyst Estimates
Track Anbio Biotechnology Class A Ordinary Shares's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Dec 30, 2025 | 0.09 | 0.00 | — |
| Apr 28, 2025 | -0.03 | 0.00 | — |
| Dec 31, 2024 | 0.09 | 0.00 | — |